FDAnews Drug Daily Bulletin
Pharmaceuticals / Commercial Operations

Fujifilm to Establish $21 Million Stem Cell Facility in Wisconsin

Jan. 14, 2019
A A

Fujifilm Cellular Dynamics, a U.S. subsidiary of Fujifilm, announced plans to invest approximately $21 million to start a stem cell manufacturing facility in Madison, Wisconsin.

The facility will have the capability to produce both small batches and industrial-sized quantities of cells. It will support Fujifilm’s internal cell therapy pipeline and serve as a contract development and manufacturing organization for its human induced pluripotent stem (iPS) cell products.

The company anticipates starting operations at the facility by March 2020, focusing on developing treatments for unmet needs, such as age-related macular degeneration, Parkinson’s disease, heart diseases and cancer.

View today's stories